The world’s largest randomised trial to date of a medical device in myocardial infarction patients was performed by applying the Swedish patient registry SWEDEHEART. No less than 7,244 patients were included in the study with minimal extra work since patient data was easily accessible.
A clear example of the power of Swedish patient registries comes from a study published in 2014 in The Lancet. Short-time survival over a six-year period (2004 – 2010) in all Swedish (390 000 patients) vs. UK patients (120 000 patients) treated for myocardial infarction was studied.
Uppsala-based U-CAN, with its continuously growing repository of unique material from longitudinal studies, welcomes collaboration projects aimed at improving diagnosis, prognosis, treatment and ultimately patient outcomes. As of spring 2016, U-CAN has already initiated such collaborations with both leading pharmaceutical companies and international cancer institutes.
The Swedish company Biovica has developed a blood test (DiviTum™) that provides accurate measures of cell-division rates in blood. Testing and validation was accelerated by ready access to blood samples from Karolinska University Hospital’s biobank. These had been collected during a clinical study including 287 women with breast cancer undergoing two different kinds of chemotherapy.
The Swedish government has made major investments in the country’s life sciences research infrastructure; the latest research bill setting new record levels. SciLifeLab and Max IV are both national resources. ESS, The European Spallation Source, which is intended to become a resource for European scientists, is under development. These resources are intended for advancing the understanding of human biology and hence leading to new innovations in the fields of prevention, diagnosis and treatment.
Sweden’s technology-driven environment, characterised as it is by close collaboration between academia, healthcare and industry, has produced many notable medtech innovations that have saved lives and alleviated symptoms for millions of patients globally. The pacemaker, the gamma knife and renal dialysis are just a few examples.
Sweden has been in the forefront of drug development for decades, not least due to the heritage from Pharmacia and Astra. Today, this legacy manifests itself through the presence of a strong, life science eco-system with a pool of competent professionals all across the value chain from world-leading academic pre-clinical and clinical research to manufacturing.
Protein research in Sweden dates back to the invention of the ultracentrifuge by The Svedberg, Nobel Laureate 1926. Since then, Sweden has held a world-class position in this field thanks to the long-standing presence of experts versed in the complexity of protein science and close interactions between health care providers and industry. Molecular and protein research is conducted in all major Swedish universities and Swedish innovations within this area are behind many solutions on the world market.